Aveanna Healthcare (AVAH)
(Delayed Data from NSDQ)
$5.23 USD
+0.20 (3.98%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $5.23 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.23 USD
+0.20 (3.98%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $5.23 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth B Momentum B VGM
Zacks News
PacBio's Stock Up on Munster Deal for Male Infertility Research
by Zacks Equity Research
PACB collaborates with the University Hospital of Munster, using Revio HiFi sequencing to advance research on male infertility and rare diseases in Germany and globally.
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device
by Zacks Equity Research
FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control procedures.
Why Fast-paced Mover Aveanna (AVAH) Is a Great Choice for Value Investors
by Zacks Equity Research
Aveanna (AVAH) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Are Medical Stocks Lagging Basilea Pharmaceutica (BPMUF) This Year?
by Zacks Equity Research
Here is how Basilea Pharmaceutica AG (BPMUF) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Should Value Investors Buy Aveanna Healthcare (AVAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Aveanna Stock Rallies 110% in 3 Months: Is It Still Worth Buying?
by Indrajit Bandyopadhyay
AVAH stock has the potential to continue its uptrend on the back of a better payer rate environment and its focus on high-paying customers.
Are You Looking for a Top Momentum Pick? Why Aveanna Healthcare (AVAH) is a Great Choice
by Zacks Equity Research
Does Aveanna Healthcare (AVAH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Despite Fast-paced Momentum, Aveanna (AVAH) Is Still a Bargain Stock
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Aveanna (AVAH) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Is Basilea Pharmaceutica (BPMUF) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Basilea Pharmaceutica AG (BPMUF) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Are Investors Undervaluing Aveanna Healthcare (AVAH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Aveanna (AVAH) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Aveanna (AVAH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Aveanna Healthcare (AVAH) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Aveanna (AVAH) delivered earnings and revenue surprises of 150% and 2.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Curious about Aveanna (AVAH) Q2 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Aveanna (AVAH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
The Pennant Group, Inc. (PNTG) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
The Pennant Group (PNTG) delivered earnings and revenue surprises of 14.29% and 7.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
by Zacks Equity Research
Here is how Amneal Pharmaceuticals (AMRX) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for July 12th
by Zacks Equity Research
IKNA, AVAH, and VEL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2024.
Is Aveanna Healthcare (AVAH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aveanna Healthcare (AVAH) and Alcon (ALC) have performed compared to their sector so far this year.
Compared to Estimates, Aveanna (AVAH) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Aveanna (AVAH) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Aveanna Healthcare (AVAH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aveanna (AVAH) delivered earnings and revenue surprises of 40% and 1.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Aveanna (AVAH) Q1 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Aveanna (AVAH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
Addus HomeCare (ADUS) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 10% and 1.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Aveanna (AVAH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Aveanna (AVAH) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Aveanna Healthcare (AVAH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aveanna (AVAH) delivered earnings and revenue surprises of 50% and 3.12%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Has Aveanna Healthcare (AVAH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aveanna Healthcare (AVAH) and Bausch Health (BHC) have performed compared to their sector so far this year.
Aveanna (AVAH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Aveanna (AVAH) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.